share_log

AIM ImmunoTech Files for US FDA IND, Fast Track for Mid-Stage Trial of Ampligen for Pancreatic Cancer

AIM ImmunoTech Files for US FDA IND, Fast Track for Mid-Stage Trial of Ampligen for Pancreatic Cancer

美国FDA Ind的AIM免疫技术文件,Ampligen治疗胰腺癌中期试验的快速通道
MT Newswires ·  2021/10/19 08:12

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发